PATENT CLAIM ANALYSIS

Application Number: 16211757
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-03
Patent Classification: ["514", "012000"]

Abstract:
The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Claim (Index 7):
The method of  claim 1 , wherein the ADNS peptide is a purified ADNS peptide comprising the amino acid sequence ERNRQAAAANPENSRGK-amide (SEQ ID NO: 2).

Metadata:
- Claim Count in Document: 9.0
- Percentile: 98.0
- Lexical Diversity: 1.2093
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14153844', '13586617', '08182183', '11572397', '13855533']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7660058958929794
- 35 USC 102 Novelty (BERT): 0.6678732293155539
- Combined Prediction Score: 0.7561926292352369
- Mean Citation Score: 458.1035599999999
- Max Citation Score: 643.7299
- Similarity Product: 638.2410960378409

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test